Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma.

Okusaka, Takuji; Ueno, Hideki; Ikeda, Masafumi; Mitsunaga, Shuichi; Ozaka, Masato; Ishii, Hiroshi; Yokosuka, Osamu; Ooka, Yoshihiko; Yoshimoto, Ryo; Yanagihara, Yasuo; Okita, Kiwamu

Okusaka, Takuji; Ueno, Hideki; Ikeda, Masafumi; Mitsunaga, Shuichi; Ozaka, Masato; Ishii, Hiroshi; Yokosuka, Osamu; Ooka, Yoshihiko; Yoshimoto, Ryo; Yanagihara, Yasuo; Okita, Kiwamu.

Afiliação

Okusaka T; National Cancer Center Hospital.
Ueno H; National Cancer Center Hospital.
Ikeda M; National Cancer Center Hospital East, Kashiwa.
Mitsunaga S; National Cancer Center Hospital East, Kashiwa.
Ozaka M; Japanese Foundation for Cancer Research.
Ishii H; Japanese Foundation for Cancer Research.
Yokosuka O; Otsuka Pharmaceutical, Tokyo.
Ooka Y; Otsuka Pharmaceutical, Tokyo.
Yoshimoto R; Chiba University Hospital, Chiba.
Yanagihara Y; Fujii Memorial Research Institute, Otsuka Pharmaceutical, Otsu.
Okita K; Shunan Memorial Hospital, Yamaguchi, Japan.

Hepatol Res ; 45(13): 1283-91, 2015 Dec.

Article em En | MEDLINE | ID: mdl-25676869

Palavras-chave

OPB-31121; advanced hepatocellular carcinoma; dose escalation; phase 1 trial; recommended dose; signal transducer and activator of transcription-3 inhibitor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Hepatol Res Ano de publicação: 2015 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Hepatol Res Ano de publicação: 2015 Tipo de documento: Article